China accounted for 41% of overall exclusive oncology deals in past five years

27 March 2024

China has emerged as a major force in the research and development of innovative therapies. Against this backdrop, Chinese companies have entered significant partnerships in the oncology therapy area in the last five years.

Amongst all the therapy areas, exclusive oncology therapy area strategic alliance deals account for 41% of the overall deals, says pharma analytics company GlobalData.

According to GlobalData’s Pharmaceutical Intelligence Center Deals Database, over the last five years (2019 to 2023), 537 strategic alliance deals were observed in China. Among these, 218 were exclusively within the oncology therapy area, contributing 41% of the overall deals.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK